[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":84},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100628104","phase-3-1-clascoterone-cream-for-the-treatment-acne-vulgaris-100628104",false,"NCT07457294","1% Clascoterone Cream for the Treatment Acne Vulgaris","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of 1% Clascoterone Cream in the Treatment of Acne Vulgaris","Inclusion Criteria:\n\n* Participants who are able to understand and comply with the protocol, voluntarily participate in the study, and sign the written informed consent form (ICF); for a participant aged \\\u003C18 years, the written ICF must be co-signed by the minor participant and a parent or legal guardian based on informed consent;\n* Age ≥12 years at the time of ICF signing, regardless of gender;\n* Diagnosis of moderate to severe acne vulgaris (including the nose) at screening and randomization, with an IGA score of 3 or 4, and facial lesions meeting the following criteria: 30-75 inflammatory lesions (papules, pustules, and nodules) and 30-100 non-inflammatory lesions (open and closed comedones);\n* Participants have used the same brand and type of skin and hair care products for at least 2 weeks prior to randomization and agree to continue the current products and regimen during the study period;\n* Female participants of childbearing potential (and their male partners) and male participants (and their female partners) must use highly effective contraception throughout the study period and for at least 3 months after the last dose of the study drug . Participants must have no plans for conception, sperm donation, or egg donation throughout the study period and for at least 3 months after the last dose of the study drug.\n\nExclusion Criteria:\n\n* Participants have more than 2 facial nodules at screening or randomization;\n* Participants have facial cysts at screening or randomization;\n* Participants have conditions at screening or randomization, which may interfere with the investigator's clinical assessments, including but not limited to: 1) Other facial dermatoses: specific types of acne (e.g., nodulocystic acne, acne conglobata, acne fulminans, etc.), secondary acne (e.g., drug-induced acne, mechanical acne, occupational acne, chloracne, etc.), or other facial rashes due to different conditions (e.g., rosacea, seborrheic dermatitis, solar dermatitis, lupus miliaris disseminatus faciei, psoriasis, eczema, etc.); 2) Facial skin or hair conditions that may interfere with clinical assessments (e.g., prominent beard, sideburns, whiskers, etc.);\n* Participants have systemic diseases with associated skin lesions: e.g., inflammatory bowel disease (Crohn's disease and ulcerative colitis), SAHA syndrome (seborrhea-acne-hirsutism-androgenetic alopecia syndrome), PCOS syndrome (polycystic ovary syndrome), SAPHO syndrome (synovitis-acne-pustulosis-hyperostosis-osteomyelitis), PAPA syndrome (pyogenic sterile arthritis-pyoderma gangrenosum-acne syndrome), hyperandrogenism-insulin resistance-acanthosis nigricans syndrome, congenital adrenal hyperplasia, etc.;\n* Prior use of the topical acne medications or therapies or Use of the systemic medications；\n* Use of skin care products with anti-acne efficacy within 2 weeks prior to randomization;\n* Participants have any serious or unstable medical condition that, in the investigator's judgment, may affect the participant's safety during the study and\u002For impede study completion, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, or psychiatric disorders.","ALL","12 Years",{"count":19,"type":20},692,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of 1% Clascoterone Cream in the treatment of acne vulgaris.\n\nTarget population: Participants aged ≥12 years with moderate to severe acne vulgaris who meet the inclusion criteria and none of the exclusion criteria.\n\nTreatment: The investigational group will receive 1% Clascoterone Cream, and the control group will receive placebo. Approximately 1 g of the cream will be applied evenly to the entire face twice daily (morning and evening) for 12 weeks.",[26],"Acne Vulgaris","NOT_YET_RECRUITING","2026-03-03",{"date":30,"type":31},"2026-03-09","ACTUAL",{"date":33,"type":20},"2026-05-04",{"date":35,"type":20},"2029-02-07",{"name":37,"class":38},"Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.","INDUSTRY",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":46,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100599164","phase-3-efficacy-and-safety-of-5-minoxidil-foam-in-female-androgenetic-alopecia-100599164","NCT07080931","Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study on the Efficacy and Safety of 5% Minoxidil Foam in the Treatment of Female Androgenetic Alopecia","Inclusion Criteria:\n\n* Voluntarily participate in the study and be able to provide a written Informed Consent Form (ICF);\n* Female aged ≥ 18 years;\n* Investigator-diagnosed androgenetic alopecia;\n* Hair loss severity graded D3 to D6 on the Savin scale;\n* Willingness to maintain identical hairstyle, hair color, and hair length at each follow-up visit;\n* No pregnancy plans during the study and for 3 months post-last dose, with commitment to highly effective contraception. Women of childbearing potential must have negative serum pregnancy test ≤7 days prior to first investigational product administration\n\nExclusion Criteria:\n\n* Trial participants with known hypersensitivity to minoxidil or any excipient of the investigational product.\n* Trial participants with known hair loss disorders other than androgenetic alopecia (AGA)\n* Trial participants with any scalp disorder at screening that may interfere with efficacy evaluation, as determined by the investigator.\n* Lactating women\n* Trial participants with history of hypotension or uncontrolled hypertension\n* Trial participants with clinically significant abnormal laboratory findings at screening that may compromise efficacy and safety assessments, as determined by the investigator.\n* Trial participants with clinically significant ECG abnormalities at screening\n* Trial participants with history of malignancy prior to screening.\n* Trial participants known to have conditions or disorders that may affect hair growth or compromise study results.\n* Trial participants with history of using systemically administered therapeutic drugs prior to screening that may interfere with efficacy evaluation, etc.\n* Trial participants with history of topical minoxidil application to alopecia-affected areas prior to screening.\n* Trial participants with no response to prior minoxidil treatment for alopecia\n* Trial participants with history of 5α-reductase inhibitor use prior to screening.\n* Trial participants with history of spironolactone or cyproterone treatment prior to screening.\n* Trial participants with history of autologous platelet-rich plasma (PRP) administration prior to screening.\n* Trial participants with history of chemotherapy, cytotoxic agents, scalp radiation, and\u002For low-level laser therapy (LLLT) or surgical scalp procedures for FAGA prior to screening.\n* Trial participants with history of using medical shampoos or solutions containing ingredients or other components that may interfere with efficacy evaluation prior to screening.\n* Trial participants planning hair transplantation during the study period, or using hair weaving, non-breathable wigs, or hair bonding during treatment.\n* Trial participants in other interventional clinical trials within 3 months before screening (excluding non-interventional studies and screen failures) , or planned concurrent clinical trial enrollment.\n* Trial participants with history of major surgery within 3 months before screening or planning major surgery during the study period.\n* Trial participants deemed by the investigator to have other conditions that may compromise compliance or render them unsuitable for the study.","FEMALE","18 Years",{"count":49,"type":20},294,[23],"The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.",[53],"Androgenetic Alopecia",[53],"RECRUITING",{"date":57,"type":31},"2026-03-05",{"date":59,"type":31},"2025-02-24",{"date":61,"type":20},"2027-12",{"name":37,"class":38},1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":73,"conditions":74,"keywords":75,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":63},"100547094","phase-3-efficacy-and-safety-of-clascoterone-cream-1-in-facial-acne-vulgaris-100547094","NCT06403501","Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris","A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Clinical Study to Evaluate the Efficacy and Safety of Clascoterone Cream 1% in Treatment of Subjects With Facial Acne Vulgaris","Inclusion Criteria:\n\n* Diagnosed with facial acne vulgaris (which includes the nose) from moderate to severe, has an Investigator's Global Assessment (IGA) score of 3 or 4; with at least 30 to a maximum of 75 inflammatory lesions (papules, pustules, and nodules) and 30 to a maximum of 100 non-inflammatory lesions (open and closed comedones);\n* Male or female, 12 years of age or older;\n* Subjects aged 18 years or older are required to provide informed consent and sign the written informed consent. A subject under 18 years of age must provide written informed assent and be accompanied by the parent or legal guardian at the time of consent signing.\n\nExclusion Criteria:\n\n* Subject has greater than two (2) facial nodules;\n* Subject has any skin pathology or condition that could interfere with the investigator's clinical evaluation of the investigational drug;\n* Subject has used topical and systemic anti-acne medications or therapies;\n* Subject has received hormonal therapy for acne treatment;\n* Subject has used a skincare product with acne removal effect;\n* Subject has other serious underlying diseases such as mental illness or malignant tumors;\n* Subject has any of the clinically significant laboratory test indicators at screening;\n* Subject has known hypersensitivity or previous allergic reaction to multiple drugs, or any of the active or inactive components of the test articles;\n* Subject engaged in drug abuse or excessive alcohol intake;\n* Subject has uncontrolled hypertension; Subject has poorly controlled diabetes;\n* Subject is pregnant, lactating, or is planning to become pregnant during the study (both male and female); subject has positive pregnancy test result; subject is unable to practice highly effective contraception methods during the trial and within 3 months after the end of the trial;\n* Subject is currently enrolled or was enrolled in other clinical trials within 3 months prior to the initiation of treatment;\n* Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this clinical trial.",{"count":19,"type":20},[23],"The primary objective of this study is to determine the safety and efficacy of clascoterone cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.",[26],[26],"2025-07-03",{"date":78,"type":31},"2025-07-09",{"date":80,"type":31},"2024-05-20",{"date":82,"type":20},"2026-10",{"name":37,"class":38},""]